BOTANIX PHARMACEUTICALS LIMITED (BOT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BOT

BOT - BOTANIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.4
Index: ALL-ORDS

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.021

02 Sep
2026

0.000

OPEN

$0.02

0.000

HIGH

$0.02

6,457,949

LOW

$0.02

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-3.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx34.5 M
Book Value Per Share xxxxxxxxxxxxxxx2.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-64.6 M
Net Profit Margin xxxxxxxxxxxxxxx-202.15 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-96.35 %
Return on Invested Capital xxxxxxxxxxxxxxx-77.88 %
Return on Assets xxxxxxxxxxxxxxx-59.36 %
Return on Equity xxxxxxxxxxxxxxx-96.35 %
Return on Total Capital xxxxxxxxxxxxxxx-68.39 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-64.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx14 M
Long Term Debt xxxxxxxxxxxxxxx11 M
Total Debt xxxxxxxxxxxxxxx26 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx37 M
Price To Book Value xxxxxxxxxxxxxxx0.82

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx94 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

30/07/2026

1

Buy

$0.14

566.67%

Canaccord Genuity maintains a Buy rating for Botanix Pharmaceuticals with a $0.14 target price following a fourth-quarter update featuring in-line sales and improving cost efficiencies.

Fourth-quarter net revenue rose 46% sequentially to $10.1m, driven by a 25% jump in prescription volumes to 33,358 and a gross-to-net yield recovery to 22% amid normalising US deductibles.

Operating cash outflows improved materially to $10.6m in the absence of active pharmaceutical ingredient purchases, while management aligned spending with high-demand territories by reducing the sales team by -11 representatives.

The analyst estimates this targeted regional strategy frees up $6m to $8m in annualised costs, providing scope to deploy savings into additional dermatology products and improve future earnings leverage.

First-quarter FY27 forecasts anticipate 37,872 scripts, supported by the Northern Hemisphere summer and a durable trajectory for Sofdra prescriptions through streamlined onboarding.
Access Extra Coverage Research History >

BOT STOCK CHART

FNArena News on BOT

1
Australian Broker Call *Extra* Edition – Jul 30, 2026

Jul 30 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 11, 2026

May 11 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 05, 2026

May 05 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Apr 22, 2026

Apr 22 2026 - Daily Market Reports
5
Rudi’s View: A Season Of Large Cap Winners

Mar 04 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
2
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
3
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
4
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
5
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
6
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
7
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
8
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
9
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
10
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps